The mission of Cancer Center Administration is to reliably and consistently provide streamlined, valuecreating administrative services that further the conduct of efficient and effective research efforts. Overall responsibilities include fiscal accountability for the financial and operational activities of KCI, management of laboratory space, coordination of Shared Resources (Cores), management of information, assistance with faculty and personnel administration including coordination of faculty recruitment, coordination of institutional research projects, and the provision of necessary administrative support to the research related activities of KCI Leadership, Program Leaders, Shared Resources and the membership. The Cancer Center Administration team members actively participate in research policy matters, strategic planning and monitoring, and support the key scientific committees, such as the Scientific Leadership Council, various advisory groups, Program meetings, and scientific retreats. The Cancer Center Administration activities of KCI do not overlap with items supported by the University's departmental structure and funding or central campus functions supported by the indirect cost recovery program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-31
Application #
8411083
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
31
Fiscal Year
2013
Total Cost
$46,329
Indirect Cost
$15,849
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55
Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58
Vaishampayan, Ulka (2018) Advantages and Adversities of the Weighted Toxicity Score. Clin Cancer Res 24:4918-4920
Wang, Zhaoxian; Sau, Samaresh; Alsaab, Hashem O et al. (2018) CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomedicine 14:1441-1454
Ravindra, Manasa; Wilson, Mike R; Tong, Nian et al. (2018) Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor ? and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. J Med Chem 61:4228-4248
Kim, Seongho; Wong, Weng Kee (2018) Extended two-stage adaptive designs with three target responses for phase II clinical trials. Stat Methods Med Res 27:3628-3642

Showing the most recent 10 out of 826 publications